188 related articles for article (PubMed ID: 19467538)
1. Ovarian control of pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in women with the polycystic ovary syndrome.
Dafopoulos K; Venetis C; Pournaras S; Kallitsaris A; Messinis IE
Fertil Steril; 2009 Oct; 92(4):1378-1380. PubMed ID: 19467538
[TBL] [Abstract][Full Text] [Related]
2. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
[TBL] [Abstract][Full Text] [Related]
3. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women.
Cheung AP; Chang RJ
Hum Reprod; 1995 May; 10(5):1054-9. PubMed ID: 7657740
[TBL] [Abstract][Full Text] [Related]
4. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonist administration in polycystic ovary syndrome.
Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
[TBL] [Abstract][Full Text] [Related]
6. Combined use of gonadotropin-releasing hormone and its analogues for ovulation induction optimization.
Filicori M
Clin Obstet Gynecol; 1993 Sep; 36(3):737-43. PubMed ID: 8403620
[No Abstract] [Full Text] [Related]
7. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
Cheung AP; Lu JK; Chang RJ
Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
[TBL] [Abstract][Full Text] [Related]
8. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
10. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
[TBL] [Abstract][Full Text] [Related]
11. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users.
Hemrika DJ; Slaats EH; Schoemaker J
Am J Obstet Gynecol; 1994 Feb; 170(2):462-8. PubMed ID: 8116698
[TBL] [Abstract][Full Text] [Related]
12. The effect of sex steroids on pituitary responsiveness to gonadotropin releasing hormone.
Eshkol A; Lunenfeld B; Insler V
J Steroid Biochem; 1975 Jun; 6(6):1061-6. PubMed ID: 1100906
[TBL] [Abstract][Full Text] [Related]
13. Effect of LHRH stimulation in anovulatory women.
Oettinger M; Psaroudakis A; Mahesh VB; Greenblatt RB
Obstet Gynecol; 1975 Jun; 45(6):614-8. PubMed ID: 1095995
[TBL] [Abstract][Full Text] [Related]
14. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome.
Lanzone A; Apa R; Fulghesu AM; Cutillo G; Caruso A; Mancuso S
Fertil Steril; 1993 Apr; 59(4):734-7. PubMed ID: 8458488
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine control in polycystic ovary-like syndrome.
Schoemaker J
Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
Blank SK; McCartney CR; Helm KD; Marshall JC
Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
[TBL] [Abstract][Full Text] [Related]
17. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
19. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome.
Billa E; Kapolla N; Nicopoulou SC; Koukkou E; Venaki E; Milingos S; Antsaklis A; Adamopoulos DA
Gynecol Endocrinol; 2009 Jul; 25(7):427-34. PubMed ID: 19533481
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of bioactive follicle-stimulating hormone secretion in women with polycystic ovary syndrome: effects of estradiol and progesterone.
Padmanabhan V; Christman GM; Randolph JF; Kelch RP; Marshall JC; Beitins IZ
Fertil Steril; 2001 May; 75(5):881-8. PubMed ID: 11334898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
